Gestational Diabetes During and After Pregnancy

Cover13; -- Gestational Diabetes During and After Pregnancy -- Dedicaiton -- Preface -- Contents -- Contributors -- 1: An Overview of Problems and Solutions in the Diagnosis and Treatment of Gestational Diabetes -- 1.18194;Introduction -- 1.28194;Controversy Regarding Screening -- 1.38194;History of GDM Screening -- 1.48194;Recent Randomized Controlled Trials-Australia -- 1.58194;Recent Randomized Controlled Trials-United States -- 1.68194;Current Screening Criteria -- 1.78194;Diagnostic Screening Cutpoints and HAPO -- References -- Section 1: Screening for and Identificationof GDM During Pregnancy -- 2: Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study -- 2.18194;Rationale for the HAPO Study -- 2.28194;Design of the HAPO Study -- 2.38194;Results -- 2.48194;Clinical Implications -- 2.58194;Appendix: HAPO Study Cooperative Research Group -- References -- 3: Evolution of Screening and Diagnostic Criteria for GDM Worldwide -- 3.1Introduction -- 3.2 Evolution of the World Health Organization Criteria -- 3.3 Evolution of the American Diabetes Association Criteria -- 3.4 Evolution of the European Association for the Study of Diabetes Criteria -- 3.5 Evolution of The Australasian Diabetes in Pregnancy Society Criteria -- 3.6 Evolution of New Zealand Society for the Study of Diabetes Criteria -- 3.7 Evolution of Japan Diabetes Society Criteria -- 3.8 Evolution of Brazilian Society of Diabetes Criteria -- 3.9 International Diabetes Federation Guidelines -- 3.10 Regional Approaches to GDM -- 3.11 Conclusions -- References -- Section 2: Burden of GDM in US Populations -- 4: Prevalence of GDM -- 4.18194;Introduction -- 4.28194;Methodological Challenges in GDM Epidemiologic Research -- 4.38194;Trends in Prevalence of GDM -- 4.48194;Conclusions and Future Research -- References -- 5: Risk Factors for Gestational Diabetes -- 5.18194;Introduction -- 5.28194;Risk Factors -- 5.38194;Modifiable Factors and GDM Risk -- 5.48194;Conclusions and Research Agenda -- References -- Section 3: Burden of GDM in Developing Countries -- 6: Burden of GDM in Developing Countries -- 6.18194;Epidemiological Studies -- 6.28194;Screening and Diagnostic Criteria in Developing Countries -- 6.38194;Adverse Pregnancy Outcomes -- 6.48194;Focus of GDM Research in China -- References -- Section 4: Pathophysiology and Genetics of GDM -- 7: Insulin and the Placenta in GDM -- 7.18194;Introduction -- 7.28194;The Human Placenta -- 7.38194;Insulin Therapy and Antidiabetic Drugs -- 7.48194;Hyperglycemia, Hyperinsulinemia and Proinflammatory Cytokines -- 7.58194;Morphological Alteration of the Placenta in GDM -- 7.68194;Functional Alteration of the Placenta in GDM -- 7.78194;Insulin Effects in the Human Placenta -- 7.88194;Placental Insulin Receptor Expression in Normal and Diabetic Pregnancy -- 7.98194;Insulin Resistance in GDM -- 7.108194;GDM Alters Placental Insulin Receptor Signaling Components -- 7.118194;Conclusion -- References -- 8: What Causes Gestational Diabetes? -- 8.1 Introduction -- 8.2 Detection: Population Screening for Glucose Intolerance -- 8.3 Glucose Regulation in Pregnancy and GDM -- 8.4 GDM and Autoimmunity to b-cells -- 8.5 GDM and Monogenic Diabetes -- 8.6G DM in the Context of Chronic Insulin Resistance -- 8.7 Implications for Diabetes Prevention -- 8.